Bozzo P, Chua-Gocheco A, Einarson A. Safety of skin care products during pregnancy. Can Fam Physician. 2011; 57:(6)665-667

Cassiano DP, Espósito ACC, da Silva CN Update on melasma—Part II: Treatment. Dermatol Ther (Heidelb). 2022; 12:1989-2012

Castilho Lopes CC, dos Santos TG, Nardi G Prevention of melasma in pregnant women: aspects of approach in aesthetic treatment. Epidemiol Int J. 2022; 6:(3)1-9

Friedman EB, Scolyer RA, Thompson JF. Management of pigmented skin lesions during pregnancy. Aust J Gen Pract. 2019; 48:(9)621-624

Grimes PE, Ijaz S, Nashawati R, Kwak D. New oral and topical approaches for the treatment of melasma. Int J Womens Dermatol. 2018; 5:(1)30-36

New prescription labeling requirements for the use of medications in pregnancy and lactation. 2016. (accessed 25 June 2023)

Skin changes in pregnancy. 2021. (accessed 25 June 2023)

Silva J, e Silva RR, Schneider MG Characteristics of physiological skin changes in pregnancy in a public maternity hospital in southern Brazil. J Dermatol Res Ther. 2022; 8

Causes and treatment of melasma during pregnancy. 2023. (accessed 25 June 2023)

What can be done to manage hyperpigmentation and melasma during pregnancy?

02 July 2023
Volume 12 · Issue 6


Pregnancy-induced hyperpigmentation and melasma are extremely common. While not associated with mortality or morbidity, these phenomena can still have a significant impact on a patient's psychological wellbeing. If treatment does commence, to ensure the safety of mother and child, careful review of the available modalities is essential. Francesca Ramadan presents an overview of the options that are considered both efficacious and safe for use during pregnancy and lactation

A woman's body undergoes tremendous changes during pregnancy, many of which are cutaneous (i.e., relating to the skin) in nature. One such change could be pigmentation, wherein certain parts of the skin grow darker in colour due to more melanin being produced. Physiological changes in melanin pigment production, due to oestrogen stimulation and elevated levels of melanocyte-stimulating hormone, are responsible for the common pregnancy-induced pigmentary phenomena (Friedman et al, 2019), which include linea nigra, an increase in pigmentation, and melasma (pigmentation particularly in the face, otherwise known as chloasma or the ‘mask of pregnancy’) (Oakley and Stanway, 2021). Linea nigra and other forms of hyperpigmentation generally appear in the first trimester and affects up to 90% of pregnant women, particularly those of colour, while melasma typically develops in the second half of pregnancy in 70% of women (Oakley and Stanway, 2021). While melasma and hyperpigmentation are not associated with adverse physical or pathological effects to either mother or baby, the psychological and psychosocial impacts of these conditions of the expectant mother can be significant. In a Brazilian descriptive study investigating physiological dermatological changes in pregnancy, 54% of the study population reported feelings of discomfort with these changes; 41.5% reported an impact on their self-esteem, and 18.7% felt that their social life had been compromised (Silva et al, 2022). However, only 14.6% received medical advice and 14.1% underwent treatment (Silva et al, 2022). This indicates the need for information on efficacious treatment modalities that do not present risk to either the pregnant woman or her developing foetus.

Register now to continue reading

Thank you for visiting Journal of Aesthetic Nurses and reading some of our peer-reviewed resources for aesthetic nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • New content and clinical newsletter updates each month